☆ 4.7 Article

Consensus Molecular Subtypes as Biomarkers of Fluorouracil and Folinic Acid Maintenance Therapy With or Without Panitumumab in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa, AIO KRK 0212)

JOURNAL OF CLINICAL ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

A. Cervantes et al.

ANNALS OF ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)

Dominik Paul Modest et al.

Summary: The PANAMA trial investigated the efficacy of adding panitumumab to maintenance therapy in patients with RAS wild-type metastatic colorectal cancer, and found that combining panitumumab with fluorouracil and folinic acid could significantly improve progression-free survival in these patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Pathology

Image-based assessment of extracellular mucin-to-tumor area predicts consensus molecular subtypes (CMS) in colorectal cancer

Huu-Giao Nguyen et al.

Summary: This study investigated the association between CMS classification and mucin-to-tumor area using a deep learning algorithm, and explored the expression of specific mucins in predicting CMS groups and clinical outcomes. The inter-observer agreement between pathologists' scores and the algorithm was excellent. The absence of mucin-expressing tumors in CMS2 provides an important phenotype-genotype correlation, and MUC5AC protein expression correlated with aggressive tumor features.

MODERN PATHOLOGY (2022)

添加到收藏夹

Article Oncology

Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.

Takayuki Yoshino et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning

Korsuk Sirinukunwattana et al.

Summary: This study utilized deep learning to analyze histological images of colorectal cancer tissue samples and successfully predicted consensus molecular subtypes, addressing the issue of molecular classification. The image-based classification method accurately identified samples that were unclassifiable by RNA expression analysis, showing potential for biological stratification.

GUT (2021)

添加到收藏夹

Article Oncology

Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1

Heinz-Josef Lenz et al.

Summary: LUME-Colon 1 was a phase III study investigating the association of colorectal cancer molecular subtypes and biomarkers with clinical outcomes. The study found that unclassified/mixed molecular subtypes may predict response to nintedanib, and there was high concordance in somatic mutations between tumor tissue and cell-free DNA.

CLINICAL COLORECTAL CANCER (2021)

添加到收藏夹

Article Oncology

Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial)

Arndt Stahler et al.

Summary: This study demonstrated that consensus molecular subtypes (CMS) can serve as additional biomarkers for sequential versus initial combination therapy in treatment-naive metastatic colorectal cancer patients. CMS2 combined with RAS/BRAF wild-type status may be a potential predictor of benefit from initial combination therapy.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology

Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone

Sanne ten Hoorn et al.

Summary: The study found that the efficacy of anti-EGFR therapy varies depending on different consensus molecular subtypes (CMSs) and primary tumor locations. The effectiveness of anti-EGFR therapy differs when using different chemotherapy backbones, showing favorable results in left-sided primary tumors with specific CMS subtypes. These findings suggest the potential for subtype-specific treatment strategies to optimize the use of anti-EGFR therapy.

BRITISH JOURNAL OF CANCER (2021)

添加到收藏夹

Article Genetics & Heredity

Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer

Peter W. Eide et al.

Summary: Gene expression-based subtypes of colorectal cancer have clinical significance, but the representativeness of primary tumors and consensus molecular subtypes (CMS) for metastatic cancers remains unclear. Metastases exhibit decreased CMS1/CMS3 signals and increased CMS4 signals, influenced by the microenvironment. The majority of classified metastases are CMS2 or CMS4, with subtype switching and inter-metastatic CMS heterogeneity being common.

NPJ GENOMIC MEDICINE (2021)

添加到收藏夹

Article Oncology

Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis

Andreas Schlicker et al.

INTERNATIONAL JOURNAL OF CANCER (2020)

添加到收藏夹

Article Oncology

Consensus molecular subtypes and CRCassigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study.

Beatrice Borelli et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

T. Andre et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

Federico Innocenti et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)

Heinz-Josef Lenz et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies

Dan Aderka et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Oncology

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer

Andrea Sartore-Bianchi et al.

ONCOLOGIST (2019)

添加到收藏夹

Article Oncology

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial

Filippo Pietrantonio et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Oncology

SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer

Y. Munemoto et al.

EUROPEAN JOURNAL OF CANCER (2019)

添加到收藏夹

Article Oncology

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

S. Stintzing et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials

Dominik Paul Modest et al.

INTERNATIONAL JOURNAL OF CANCER (2019)

添加到收藏夹

Article Oncology

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)

Thomas Aparicio et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

J. K. Mooi et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

E. Aranda et al.

EUROPEAN JOURNAL OF CANCER (2018)

添加到收藏夹

Article Oncology

Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study

K. K. H. Goey et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Review Oncology

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis

Filippo Pietrantonio et al.

EUROPEAN JOURNAL OF CANCER (2015)

添加到收藏夹

Article Oncology

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial

Susanna Hegewisch-Becker et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

The consensus molecular subtypes of colorectal cancer

Justin Guinney et al.

NATURE MEDICINE (2015)

添加到收藏夹

Article Oncology

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

J. Y. Douillard et al.

ANNALS OF ONCOLOGY (2014)

添加到收藏夹

Article Oncology

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer

Lee S. Schwartzberg et al.

JOURNAL OF CLINICAL ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study

Benoist Chibaudel et al.

JOURNAL OF CLINICAL ONCOLOGY (2009)

添加到收藏夹

Article Oncology

OPTIMOX1:: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer -: A GERCOR study

C Tournigand et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

添加到收藏夹

Article Oncology

Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers

WS Samowitz et al.

CANCER RESEARCH (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.